Johnson & Johnson (NYSE:JNJ) Recalls Anti-Seizure Drug

tdp2664
E money daily
Johnson & Johnson (NYSE:JNJ) has decided to recall two lots of its Topamax anti-seizure drug. Johnson & Johnson (NYSE:JNJ) Recalls Anti-Seizure Drug Due to complaints of uncharacteristic odor associated with the drug, Johnson & Johnson (NYSE:JNJ) company is recalling about 57,000 bottles of its Topamax epilepsy and migraine drug from the market. Chemical treatment on wooden pallets in the lot is said to be the reason for this odor. A Johnson & Johnson (NYSE:JNJ) spokeswomen said, "The recall involves two lots of 100-milligram tablets totaling 57,000 bottles. Each bottle contains 60 tablets. The company believes only 6,000 bottles remain on the marketplace that have not been consumed." Johnson & Johnson (NYSE:JNJ) shares were at 60.02 at the end of the last day’s trading. There’s been a -4.6% change in the stock price over the past 3 months. Johnson & Johnson (NYSE:JNJ) Analyst Advice Consensus Opinion: Hold Mean recommendation: 2.27 (1=Strong Buy, 5=Strong Sell) 3 Months Ago: 2 Zack’s Rank: 14 out of 14 in the industry